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The use of botulinum neurotoxin type A (BoNT/A) has 
become a recognised second-line treatment modality for 
symptomatic patients with idiopathic (IDO) and neuro-
pathic detrusor overactivity (NDO). In the United King-
dom (UK) the treatment is administered in those for whom 
conservative measures and antimuscarinics have failed, as 
stated in the National Institute for Health and Clinical 
Excellence (NICE) guidance on urinary incontinence (UI) 
in women.1 Its use is also recommended by the European 
Association of Urology (EAU)2 and was given a grade A 
recommendation by an expert panel from Europe related 
to its efficacy.3 Furthermore, a large comprehensive sys-
tematic review by Mangera et al. confirmed that the toxin 
was efficacious in various forms of lower urinary tract 
dysfunction, including detrusor overactivity (DO).4 As 
there are different formulations and different companies 
manufacturing and marketing BoNT/A, the United States 
(US) Food and Drug Administration (FDA) have revised 
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Abstract
Background: Botulinum toxin-A (BoNT/A) is now established second-line management for refractory overactive 
bladder (OAB) and recognised in many incontinence guidelines and pathways. For those with neurogenic detrusor 
overactivity secondary to spinal cord injury or multiple sclerosis, the toxin is currently licensed in certain parts of the 
world, including the UK. It is an effective treatment in those in whom antimuscarinics and conservative measures have 
failed who have symptoms of OAB and or detrusor overactivity (DO). 
Methods: Treatment can be given in an outpatient setting and can be administered under local anaesthesia. Its efficacy 
lasts for between six and 12 months. 
Results: It has an acceptable safety profile with the biggest risk being urinary tract infection and difficulty emptying the 
bladder, necessitating clean intermittent self-catheterisation (CISC). Medium-term follow-up suggests repeated injections 
are also safe and efficacious. 
Conclusions: The mechanism of action of the toxin is more complicated than originally thought, and it seems likely 
that it affects motor and sensory nerves of the bladder. In the last 10 years much of the progress of this treatment from 
early experimental trials to mainstream clinical use, and a better understanding of how it works in the bladder, are as a 
result of research conducted in the UK. This review summarises the significant and substantial evidence for BoNT/A to 
treat refractory OAB from UK centres.
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the nomenclature for the toxin, especially as dosing 
between Botox® (Allergan, Ltd, Irvine, USA) and Dys-
port® (Ipsen, Ltd, Paris, France) are different. Botox® is 
now known as onabotulinumtoxin A and Dysport® as 
abobotulinumtoxin A.
Onabotulinumtoxin A has been approved for urological 
use in the bladder to treat NDO secondary to spinal cord 
injury (SCI) or multiple sclerosis (MS) in certain parts of 
the world, including the US and the UK. Soon-to-be-
reported-on phase III pivotal multi-centre clinical trials will 
facilitate its licensing in IDO in the future.
This article highlights the research contribution from the 
UK, which is significant, on this remarkable toxin and its 
use in the bladder.
Mechanism of action
The effect of BoNT/A on inhibiting parasympathetic presynap-
tic release of acetylcholine (ACh) at the neuromuscular junction 
is well known. BoNT/A neurotoxin binds to peripheral cholin-
ergic terminals and inhibits ACh release at the neuromuscular 
junction. Four steps are involved in this process: binding, 
translocation, cleavage and inhibition of transmitter release, 
resulting in blockage of synaptic transmission and flaccid 
paralysis in the target muscle ensues5 (Figures 1 and 2).
A dual mechanism of action for BoNT/A on both the 
efferent and afferent arms of the micturition reflex has been 
proposed.6 Studies of human bladder biopsies taken at four 
and 16 weeks following onabotulinumtoxin A injections 
have shown a reduced expression of vanilloid (TRPV1) and 
purinergic (P2X3) receptors in the sub-urothelium of patients 
with NDO and IDO.7 Both these sensory receptors are up-
regulated in IDO and NDO at baseline, and their levels by 
16 weeks normalise to that of controls following administra-
tion of either 200 or 300 IU of onabotulinumtoxin A.
A potential concern with repeated BoNT/A injections is 
bladder wall fibrosis and its sequelae. Bladder biopsies 
were taken before and four and 16 weeks after the first and 
repeated injection of BoNT/A.8 A total of 179 biopsies from 
79 patients were analysed for inflammatory changes, fibro-
sis, hyperplasia and dysplasia. The severity of inflamma-
tion remained unchanged, even after repeat injections of 
onabotulinumtoxin A. Equal levels of fibrosis (2.2%) were 
seen pre- and post-injection. No evidence of dysplasia or 
hyperplasia were detected and no significant difference 
existed between NDO or IDO.
Figure 1(a).  For exocytosis to occur SNARE proteins are 
required to anchor the acetylcholine-containing vesicles to 
the neuronal membrane. SNARE: soluble N-ethylmaleimide-
sensitive-factor attachment protein receptor; SNAP-25: 
synaptosomal-associated protein 25.
Figure 1(b). Acetylcholine is released into the neuromuscular 
cleft where it will bind to muscarinic receptors on the muscle end 
plate and cause contraction. 
SNARE: soluble N-ethylmaleimide-sensitive-factor attachment protein 
receptor.
Figure 2(a).  BoNT/A binds to the SV2 receptor and is 
internalised. The heavy chain of the toxin facilitates entry.
BoNT/A: botulinum toxin-A; SV2: synaptic vesicle glycoprotein 2.
Figure 2(b). The light chain of the toxin acts as an enzyme 
and cleaves the various SNARE protein components. In the case 
of BoNT/A, it cleaves SNAP-25, which prevents acetylcholine 
release and hence flaccid paralysis ensues in the target muscle.
SNARE: soluble N-ethylmaleimide-sensitive-factor attachment protein 
receptor; BoNT/A: botulinum toxin-A; SNAP-25: synaptosomal-
associated protein 25.
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BoNT/A, when injected into the prostate, has been 
shown to reduce prostate size by apoptotic mechanisms.9 
As a result BoNT/A has been trialled in humans to treat 
benign prostatic hyperplasia and is reviewed elsewhere.10 
To assess whether apoptosis is significant for the mode of 
action in the bladder, biopsies were taken from 12 patients 
with NDO secondary to multiple sclerosis and seven 
healthy controls, before and four weeks after onabotuli-
numtoxin A injections. Identification of apoptotic cells was 
performed using terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling (TUNEL) staining. No 
difference between the two groups was demonstrated, sug-
gesting that apoptosis is not likely to be a significant factor 
contributing to the mechanism of action in the bladder.10
Recent evidence suggests interstitial cells of Cajal-like 
cells (ICC) in the bladder suburothelium may act as ‘mech-
ano-receptors’ with implications in the pathophysiology of 
DO.11,12 In the bladder, these cells form a matrix, separated 
by gap junctions, extensively coupled with connexin 43 
(Cx43), and closely associated with the afferent nerves on 
electron microscopy. A study assessing suburothelial biop-
sies suggested Cx43 was increased in NDO and IDO when 
compared with control biopsies; however, this remained 
unchanged after BoNT/A injections.13 No significant dif-
ferences were seen in ICC marker (vimentin, c-kit) immu-
noreactivity when related to controls or BoNT/A 
administration. The authors concluded that the beneficial 
effect of BoNT/A in suppressing DO is unlikely to be 
caused by remodelling of the gap junction distribution, at 
least in the suburothelium.
Datta et al. recently assessed muscarinic receptors in the 
human urothelium and suburothelium and the effects of 
onabotulinumtoxin A.14 The expression of muscarinic recep-
tors was decreased in patients with DO. Successful DO treat-
ment with onabotulinumtoxin A appeared to normalize M1, 
M2 and partly M3 receptor levels. Baseline and post-treatment 
changes in these muscarinic receptor levels were inversely 
associated with patients’ overactive bladder (OAB) symptoms 
and increased with an improvement in patient symptoms. 
Concomitant antimuscarinic use did not seem to affect results. 
The authors concluded, however, that the functional signifi-
cance of such results remain as yet to be determined.
Technique of injection
The original description of BoNT/A injections for the treat-
ment of NDO was through a collagen flexible needle using 
a rigid cystoscope.1,15 Utilising this technique, a magnetic 
resonance imaging (MRI) study in six patients following 
BoNT/A injections mixed with contrast showed the major-
ity of the toxin to be in the detrusor muscle (82%) but some 
of the contrast material was seen to be situated in the 
perivesical fat tissue outside the detrusor. The technique 
employed utilised a rigid cystoscope and a 22 G needle and 
had a needle length of 8 mm which was inserted into the 
bladder wall and withdrawn halfway prior to injection.16 In 
an open-label study using onabotulinumtoxin A for NDO 
and IDO patients commenced in 2002,17 clinicians began 
exploring an alternative method of delivering the treatment 
using a flexible cystoscope and an ultra-fine 4 mm length 
flexible needle (Olympus, Keymed, UK) performing injec-
tions in an outpatient setting under local anaesthesia.18 The 
objective was to ensure that the toxin could be delivered at 
an optimal depth into the sub-mucosa or detrusor muscle, 
but not beyond. A fine sheath (27 G) was introduced 
through the working channel of the cystoscope and the 
ultra-fine needle was passed through this sheath. This pro-
vided needle stability, injection precision and protection to 
the cystoscope. As the ultra-fine needle is buried into the 
bladder mucosa, a depth of 4 mm will not be exceeded and 
the chance of backflow of the toxin after removal of the 
needle is reduced. Several companies have developed their 
own injection needles in light of the recent licensing of 
onabotulinumtoxin A in NDO, all with slightly different 
characteristics. The exact location of injection and at what 
depth, injection number and volume of injection have not 
been standardised, with some arguing this is unlikely to 
alter efficacy in a significant way. However, a recent study 
by Manecksha et al. looked at trigone-inclusive (20 injec-
tions — five in the trigone and 15 outside the trigone in the 
bladder) versus trigone-sparing (20 injections throughout 
the bladder) abobotulinumtoxin A (500 IU total) injections 
into the bladder to treat refractory OAB.19 Utilising the 
overactive bladder symptom score (OABSS), significant 
reductions were seen in the overall score and in the urgency 
subscale in favour of the trigone-inclusive technique.
NDO
Popat et al. in an open-labelled study compared the effect 
of onabotulinumtoxin A injections at 200 IU for IDO and 
300 IU for NDO.3,17 Significant improvements were dem-
onstrated in IDO as well as NDO for OAB symptoms, 
urodynamics and quality of life (QoL);20 however, urgency 
was significantly better with NDO compared to IDO at 
four and 16 weeks. When looking at IDO and NDO 
patients as a whole, Kalsi et al. found that the improve-
ment in QoL correlated well with improvements in OAB 
symptoms but not with urodynamic parameters.20 The 
speed of the effect was obvious to patients and clinicians. 
Kalsi et al. have reported on NDO patients treated with 
300 IU onabotulinumtoxin A and assessed patients with a 
seven-day voiding diary immediately after injection.21 
Significant improvements compared to baseline were 
demonstrated as early as two days for urgency, frequency 
and nocturia and by day 3 for urge UI.
Patki et al. utilised abobotulinumtoxin A in their series of 
37 SCI patients and concluded that 1000 IU was effective in 
treating NDO, with improvements in QoL scores and urody-
namic parameters. Additionally 50% of patients were able to 
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stop antimuscarinic medication.22 However, two cases of 
transient muscle weakness were observed with this dose. The 
mean duration of benefit was approximately nine months in 
this study. The same group also reported on patients’ satisfac-
tion in a group of patients with SCI and NDO also treated 
with abobotulinumtoxin A.23 In this study mean patient satis-
faction scores were 6.2/10, and 90% of patients selected the 
option to have BoNT/A treatment as their long-term treat-
ment option. Only 15% wished to consider a permanent 
alternative solution such as augmentation cystoplasty.
Large numbers of studies have been conducted examin-
ing the effect of BoNT/A in patients with various causes of 
spinal cord dysfunction especially after spinal injury. 
Relatively little was known about patients with MS, which 
can cause debilitating bladder symptoms. A prospective 
study of 43 patients with MS who suffered from severe 
urge incontinence demonstrated the efficacy of onabotuli-
numtoxin A in this setting.24,25 Patients were followed up at 
four and 16 weeks, with significant improvements found in 
QoL and urodynamic parameters, with a mean duration of 
effect of 9.7 months. Although this effect was sustained 
with repeat treatments, it was noticed that 98% of patients 
had to perform CISC after treatment.
The recent licensing of onabotulinumtoxin A has been 
on the background of recent company-sponsored multi-
centre phase III randomised controlled trials, of which 
one involved several UK centres.26 Two hundred and sev-
enty-five patients were randomised to onabotulinumtoxin 
A at 200, 300 U and placebo. Patients with MS and SCI 
who had ≥ 14 UI episodes per week were recruited. The 
primary endpoint of UI episodes at six weeks was signifi-
cantly reduced with onabotulinumtoxin A at both doses 
compared with placebo. At this timepoint fully continent 
rates were 7.6%, 38% and 39.6% for placebo, 200 U and 
300 U, respectively. Incontinence QoL scores were also sig-
nificantly greater at six weeks, suggesting improved QoL in 
those treated with onabotulinumtoxin A compared with pla-
cebo. The median duration of effect of onaboutlinumtoxin A 
was 42.1 weeks in contrast to placebo, which was 13.1 
weeks. Seventy-four patients received a second injection 
with similar benefits. Approximately 50% were not per-
forming CISC at baseline. The need to instigate CISC was 
12%, 30% and 42% in the placebo, 200 U and 300 U groups, 
respectively. The study concluded 200 U was equivalent 
to 300 U but with a better safety profile. Although typi-
cally open-labelled studies utilised 300 U for treating 
NDO, on the basis of the phase II and III clinical trial data 
it is likely the initial recommended dose for this patient 
population will be 200 U onabotulinumtoxin A.
IDO
In an open-labelled study, Kalsi et al. looked at when OAB 
symptoms change following onabotulinumtoxin A injec-
tions at 200 IU in IDO patients.21 The study showed   
frequency, urgency and urge UI was significantly reduced 
by day 4 following treatment. Nocturia took longer to 
reduce significantly. Urgency remained significantly 
reduced after day 4 up until week 4 but frequency and urge 
UI were a little more variable, although by week 4 all OAB 
symptoms including nocturia were significantly less com-
pared to baseline. In another study assessing IDO and NDO 
patients, the same institution reported on significant 
improvements in QoL as assessed by the Urogenital Dis-
tress Inventory-6 (UDI-6) and Incontinence Impact Ques-
tionnaire-7 (IIQ-7) at four and 16 weeks post-treatment 
compared to baseline.20 This study found a statistically 
proven correlation between improvement in QoL with 
improvements in urgency and urge UI for IDO and NDO 
patients and also frequency in the NDO population alone. 
Khan et al. have recently published data on patient-reported 
outcomes of incontinence using two out of the six questions 
on the UDI-6.27 In this open-labelled study in which the 
data were collected four weeks’ post-injection in 74 
patients, complete continence rates in previously inconti-
nent patients were reported as 51%. In all patients, includ-
ing those for whom complete continence was not achieved, 
significant improvements in OAB parameters were still 
observed.
Another study from the UK, the first to report on the use 
of Dysport® in IDO, utilised 500 U of abobotulinumtoxin A 
with significant benefit.28 In this study all patients had urge 
UI pre-injection. Sixty-three per cent of patients were dry at 
one week and 32% at three and six months. Significant 
reductions in frequency and urgency were seen for up to six 
months compared to baseline. Pad usage was significantly 
less after six weeks of treatment. Although trends of improve-
ment were seen in urodynamic parameters, only first desire 
to void was significantly increased in BoNT/A-treated 
patients at three months. DO seen in 100% pre-injection had 
resolved in 40% by three months. High rates of voiding dys-
function were seen, with 35% requiring a suprapubic cathe-
ter or CISC at six weeks’ follow-up.
The first double-blind placebo-controlled trial with 
onabotulinumtoxin A and IDO patients refractory to anti-
muscarinics was reported in 2007.29 Patients were ran-
domised to 200 U (Botox®) (n=16) or placebo (n=18) 
administered using a flexible cystoscopic technique under 
local anaesthetic. The primary endpoint, maximum cysto-
metric capacity, increased significantly, and improvement in 
symptoms, urodynamic and QoL parameters using the 
UDI-6 and IIQ-7 was seen in patients in the BoNT/A group 
compared with placebo. Unblinding took place after 12 
weeks, and data from the open-labelled extension study sug-
gested the beneficial effects lasted at least for 24 weeks. Six 
patients, all in the onabotulinumtoxin A group, had sympto-
matic >150 ml residual volume at follow-up and were taught 
CISC. Further studies have confirmed that at this dose the 
incidence of CISC is approximately 40%.24,30 A larger mul-
ticentre, randomised, double placebo-controlled trial of 240 
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female patients with refractory IDO (RELAX study), among 
eight UK urogynaecology centres, has been published also 
confirming the efficacy of onabotulinumtoxin A at 200 U.31 
Outcomes such as voiding frequency per 24 hours, urgency 
and incontinence episodes were all significantly improved 
in the treatment arm over placebo. Continence was more 
common following toxin treatment compared to placebo, 
31% vs 12%. Rates of UTI and self-catheterisation were 
also significantly raised in the treatment groups at 31% and 
16%, respectively. Finally a dose-escalation multicentre 
company-sponsored trial involving UK centres has reported 
that at week 12 mean change from baseline in urinary 
urgency incontinence (UUI) episodes was –17.4, –20.7, 
–18.4, –23.0, –19.6 and –19.4 for the placebo and onabotu-
linumtoxin A dose groups of 50, 100, 150, 200 and 300 U, 
respectively. Dry rates were 15.9%, 29.8%, 37.0%, 40.8%, 
30.9% and 57.1% in the placebo, and 50, 100, 150, 200 and 
300 U dose groups, respectively. Although a clear placebo 
effect is seen, there were statistically significant differences 
between active treatment and placebo at various timepoints. 
Using non-parametric analysis and a rank residual score, a 
dose-dependent effect was observed with minimal addi-
tional benefit for this parameter with doses > 150 U. The 
lowest dose of 50 U did not appear to be as effective as 
doses 100–300 U. Those with DO or not had similar bene-
fits. Dose-dependent increases in post-void residual urine 
volume (PVR) were observed up to 200 U. The maximal 
effect of increased PVR was at two weeks and thereafter 
values declined to 36 weeks. Adverse events reported sig-
nificantly higher in the onabotulinumtoxin A groups com-
pared with placebo were high PVRs and urinary tract 
infection (UTI). The percentage of patients requiring an 
indwelling catheter or CISC were 0, 5.4, 10.9, 20.0, 21.2 
and 16.4% for placebo, 50, 100, 150, 200 and 300 U, 
respectively. The phase III data are currently awaited but it 
is likely that onabotulinumtoxin A doses of 100–150 U will 
be recommended in the first instance.
As experience with using BoNT/A to treat OAB 
increased, clinicians became aware of its significant benefits 
but also of some limitations. Patient selection was crucial 
and furthermore not every patient had a good or excellent 
response. Some patients did not respond to treatment and 
some potential drawbacks such as voiding dysfunction 
necessitating CISC, which were far more prevalent than 
originally described, became apparent. In one study assess-
ing poor IDO responders, high maximum detrusor pres-
sures (MDP) during filling cystometry of > 110 cm H20 
was predictive of a poor response to treatment with 200 U 
onabotulinumtoxin A.32 In such patients, the authors 
reported, with higher doses successful outcomes were pos-
sible. The same group also assessed the need for CISC fol-
lowing BoNT/A and found simple-to-calculate detrusor 
contractility variables from urodynamic data such as pro-
jected isovolumetric pressure-1 and bladder contractility 
index may be helpful in predicting CISC and be helpful in 
counselling patients.33 However, these findings need to be 
confirmed in larger-scale studies. This study as well as 
another study assessing onabotulinumtoxin A at 300 U in 
female patients with IDO have shown detrusor contractil-
ity does reduce following treatment, confirming its likely 
effect on efferent blockade. Interestingly, improvements in 
the QoL offered by onabotulinumtoxin A remain despite 
the need for CISC. In a prospective study, 65 women with 
refractory IDO were treated with 200 IU.34 No signifi-
cant differences in the degree of QoL score improvement 
were seen pre- and post-treatment between those who 
required CISC and those who did not. The group con-
cluded that there is no impairment to the QoL in those 
who require CISC after onabotulinumtoxin A once 
appropriately informed of the risks.
An interesting retrospective study at a large UK 
teaching hospital followed up patients up to 60 months 
after their first injection.35 From this analysis, it appeared 
that almost two thirds of patients (61.3% to 63.8%) had 
discontinued BoNT/A treatment by 36 to 60 months, 
respectively. The main reasons for this were tolerability 
issues due to the need for CISC and UTI. Loss of efficacy 
was of secondary importance in these patients. This study 
highlights the possible issues of real-life practice outside 
clinical trials, and in their hands drop-out rates are high 
with patients pursuing other treatments, such as conserv-
ative, neuromodulation and surgical interventions. 
However, Dowson et al. found that drop-out rates were 
approximately 25% after injections 1 and 2 and thereafter 
none.36 Discontinuation rates were also associated mainly 
with poor efficacy in 13% and CISC issues in 11%. 
Efficacy was maintained for up to five injections accord-
ing to analyses with significant improvements in OAB 
symptoms and QoL parameters in this large prospective 
cohort. Khan et al prospectively followed 81 patients 
treated with 200U of onabotulinumtoxin A for IDO in a 
non-randomised, open label study.30 Significant improve-
ments in symptom scores were noticed using the UDI-6 
and the IIQ after up to five repeated injections. The over-
all CISC rate after treatment was 43% with residual vol-
umes of over 100 ml being considered significant. 
Another study assessed altering the dose of the toxin in 
order to maximise efficacy and/or limit the need for 
CISC and reported on repeated injection outcomes.37 
Patients had received up to four injections and signifi-
cant improvements in OAB symptoms and QoL were 
observed after each injection as compared with baseline. 
Urodynamic parameters also improved with no evidence 
of reduced compliance. Nine patients had their BTX-A 
dose altered, with better outcomes in five.
Cost effectiveness
In the UK a cost effectiveness analysis for onabotulinum-
toxin A was conducted.38 Although a cost per quality-
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adjusted life year (QALY) gained calculation was not 
possible because of the lack of data linking bladder 
symptoms of DO to utility data needed to calculate 
QALYs gained, costings of the procedure were calcu-
lated based on National Health Service (NHS) standard 
costs and NHS resources used by typical patients. The 
overall costs of one set of onabotulinumtoxin A injec-
tions, including clinic consultation, basic investigations 
such as urine dipstick and an urodynamic study, the 
injection procedure with consumables, clinic review in 
the outpatient clinic post-injection with a further urine 
dipstick and post-void residual, equated to £745.33 for 
IDO and £874.62 for NDO.
Conclusion
BoNT/A is now recognised as an effective therapeutic 
option to treat refractory DO. Over the last 10 years the UK 
has contributed significantly to the literature on the effects 
of this toxin in the clinical setting. Basic science research 
has given some valuable insight into its potential mecha-
nism of action. It is hoped that soon it will receive a licence 
for OAB/IDO so that patients in need throughout the UK 
will have access to the beneficial effects of the toxin. Future 
study will concentrate on optimising its delivery to the 
bladder, assessing other bladder conditions beyond OAB in 
vigorous clinical trial settings and further developing an 
understanding of its complex mode of action.
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